Q2 2026 13F · SEC CIK 2011932

Exome Asset Management LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $162.1M
Reported positions: 52
Top holdings a year, 3 yrs: +38.0%
Assets under management: $548.6M

Exome Asset Management LLC is a hedge fund that reported 52 positions worth $162.1M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Guardant Health Inc (GH, 6.2%), Praxis Precision Medicines I (PRAX, 5.6%), TG Therapeutics Inc (TGTX, 5.6%). A portfolio copying its top holdings returned 38.0% a year over the last 3 years, against 18.4% for the S&P 500.

Exome Asset Management LLC holdings largest 50 of 52 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Exome Asset Management LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
GHGuardant Health Inc	6.2%	4.5%	67,500	-18.4%	$10.1M
PRAXPraxis Precision Medicines I	5.6%	8.6%	27,205	-40.2%	$9.1M
TGTXTG Therapeutics Inc	5.6%	New	164,915	—	$9.1M
COGTCogent Biosciences Inc	5.0%	6.3%	210,523	-24.4%	$8.1M
IONSIonis Pharmaceuticals Inc	4.3%	4.9%	88,177	-19.9%	$7.0M
LLYEli Lilly & Co	4.1%	3.8%	5,492	-21.7%	$6.6M
ABVXAbivax SA	3.9%	New	46,878	—	$6.2M
ALMSAlumis Ord	3.5%	3.6%	204,418	-26.8%	$5.8M
CYTKCytokinetics	3.2%	4.0%	60,056	-42.1%	$5.1M
ELVNEnliven Therapeutics Inc	3.1%	5.1%	100,203	-54.5%	$5.1M
VERAVera Therapeutics Inc Class A	2.6%	2.7%	97,276	-15.4%	$4.2M
UNHUnitedhealth Group Inc	2.5%	2.0%	9,612	-25.3%	$4.0M
TXG10x Genomics Inc	2.4%	1.9%	102,629	-33.4%	$3.9M
NTRANatera Inc	2.3%	2.2%	13,800	-26.0%	$3.7M
QUREUniqure NV	2.3%	New	81,056	—	$3.7M
RYTMRhythm Pharmaceuticals Inc	2.2%	2.1%	32,209	-20.6%	$3.6M
MAZEMaze Therapeutics Inc	2.1%	1.6%	114,692	+29.6%	$3.4M
GLUEMonte Rosa Therapeutics Inc	2.0%	1.7%	137,115	-23.6%	$3.3M
MLTXMoonlake Immunotherapeutics	2.0%	2.4%	166,493	-22.7%	$3.2M
ALKSAlkermes PLC	2.0%	1.8%	61,336	-27.1%	$3.2M
LQDALiquidia Corporation	1.9%	1.0%	39,224	-14.4%	$3.1M
UTHRUnited Therapeutics Corp Del	1.8%	2.5%	5,410	-23.3%	$2.9M
GKOSGlaukos Corp	1.7%	1.3%	19,862	-4.8%	$2.8M
ARWRArrowhead Pharmaceuticals in	1.6%	1.7%	32,214	-29.5%	$2.6M
AGIOAgios Pharmaceuticals Inc	1.6%	2.5%	70,500	-43.6%	$2.6M
CBIOCrescent Biopharma Inc	1.4%	1.7%	127,769	-16.6%	$2.3M
AZNAstrazeneca PLC	1.4%	New	12,045	—	$2.3M
BSXBoston Scientific Corp	1.3%	1.8%	48,347	+0.0%	$2.1M
ADAGAdagene Inc	1.3%	1.7%	488,293	-33.7%	$2.1M
PENPenumbra, Inc.	1.2%	1.2%	6,300	+0.0%	$2.0M
ISRGIntuitive Surgical Inc	1.2%	1.7%	4,908	-22.8%	$2.0M
VKTXViking Therapeutics Inc	1.2%	New	47,861	—	$1.9M
OCULOcular Therapeutix Inc	1.1%	New	181,588	—	$1.8M
EQEquillium Inc	1.1%	New	552,956	—	$1.8M
ASNDAscendis Pharma A/s	1.1%	New	6,573	—	$1.8M
CRBPCorbus Pharmaceuticals Hldgs	1.1%	1.3%	184,914	-21.0%	$1.7M
CTMXCytomx Therapeutics Inc.	1.1%	1.4%	460,067	-11.8%	$1.7M
VSTMVerastem Inc	1.0%	2.0%	429,041	-32.6%	$1.6M
NKTRNektar Therapeutics	1.0%	New	22,417	—	$1.6M
CLPTClearpoint Neuro Inc	0.9%	New	83,636	—	$1.5M
INSMInsmed Inc	0.9%	2.6%	13,873	-47.9%	$1.5M
CAICaris Life Sciences Inc	0.9%	New	78,180	—	$1.4M
BBIOBridgebio Pharma Inc	0.8%	2.9%	18,359	-72.8%	$1.4M
ZBIOZenas Biopharma Inc	0.8%	0.9%	52,443	-35.0%	$1.3M
IMABNovabridge Biosciences	0.7%	0.8%	576,960	+0.0%	$1.1M
ESTAEstablishment Labs Hldgs Inc	0.7%	0.4%	13,100	+0.0%	$1.1M
RLAYRelay Therapeutics Inc	0.5%	1.6%	47,531	-82.9%	$889K
GERNGeron Corp	0.5%	New	624,046	—	$799K
10919W405Bright Minds Biosciences Inc	0.4%	New	10,110	—	$710K
CMPXCompass Therapeutics Inc	0.4%	New	276,165	—	$605K

What Exome Asset Management LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +81.8% /yr; S&P 500 +20.1%
3 years: +38.0% /yr; S&P 500 +18.4%
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$162.1M	52
Q1 2026	$169.9M	45
Q4 2025	$202.4M	53
Q3 2025	$151.4M	54
Q2 2025	$121.3M	55
Q1 2025	$111.6M	49
Q4 2024	$132.9M	58
Q3 2024	$145.6M	56
Q2 2024	$112.3M	52
Q1 2024	$116.8M	53
Q4 2023	$101.1M	52

Questions about Exome Asset Management LLC's portfolio

What stocks does Exome Asset Management LLC own?

Exome Asset Management LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 52 positions worth $162.1M. The largest are Guardant Health Inc (GH) at 6.2%, Praxis Precision Medicines I (PRAX) at 5.6%, TG Therapeutics Inc (TGTX) at 5.6%, Cogent Biosciences Inc (COGT) at 5.0% and Ionis Pharmaceuticals Inc (IONS) at 4.3%.

What did Exome Asset Management LLC buy last quarter?

In Q2 2026, Exome Asset Management LLC added a new position in TG Therapeutics Inc (TGTX), a new position in Abivax SA (ABVX), a new position in Uniqure NV (QURE), a new position in Astrazeneca PLC (AZN), a new position in Viking Therapeutics Inc (VKTX) and Maze Therapeutics Inc (MAZE) (+29.6% shares), compared with its Q1 2026 filing.

What did Exome Asset Management LLC sell last quarter?

In Q2 2026, Exome Asset Management LLC cut from its top 50 Elevance Health Inc Formerly (ELV), cut from its top 50 Apellis Pharmaceuticals Inc (APLS), cut from its top 50 Avalo Therapeutics Inc (AVTX), cut from its top 50 Soleno Therapeutics Inc (SLNO), cut from its top 50 4d Molecular Therapeutics in (FDMT), Relay Therapeutics Inc (RLAY) (-82.9% shares), Bridgebio Pharma Inc (BBIO) (-72.8% shares) and Enliven Therapeutics Inc (ELVN) (-54.5% shares), compared with its Q1 2026 filing.

How has Exome Asset Management LLC's portfolio performed?

A portfolio copying Exome Asset Management LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +38.0% a year over the last 3 years, against +18.4% for the S&P 500. Over 1 year: +81.8% against +20.1%.

When is Exome Asset Management LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Exome Asset Management LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Exome Asset Management LLC manage?

Exome Asset Management LLC reported $548.6M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $162.1M.